SITE SEARCH

Cefaclor News

Thursday 30 March 2006

Community-associated methicillin-resistant staphylococcus aureus outbreaks seen among healthy neonates

In 2004, hospitals in Chicago and Los Angeles County reported clusters of skin infections caused by methicillin-resistant Staphylococcus aureus (MRSA) among otherwise healthy infants within the first month after birth.

[more]
Monday 05 September 2005

Teva Announces Approval of Cefaclor ER Tablets

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has approved the Company’s ANDA for Cefaclor Extended Release Tablets USP, 375 mg and 500 mg.

[more]
Monday 25 July 2005

The latest word on penicillin allergy

Despite a myriad of studies over the past several decades using varied patient populations, the true increased risk of an allergic reaction to a cephalosporin in a patient with a penicillin allergy compared with a primary (and...

[more]
Thursday 24 June 2004

Ranbaxy launches chewable cefaclor

The US subsidiary of India’s Ranbaxy has launched a cephalosporin antibiotic in a chewable tablet formulation designed to be easier to take by patients who struggle with tablets or capsules.

[more]

This site is intended solely for U.S. audiences; products described here may be subject to different medical and/or regulatory requirements in other countries. This site is for educational purposes only; information contained within should not be used to diagnose or treat a health problem or disease. Please consult a licensed health care provider regarding your medical condition.The products mentioned are trademarks of their respective owners.